Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14601538 | 0.91 | KMT2A (0.43) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL1129051 | 0.86 | KMT2A (0.40) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL3269719 | 0.85 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL171627 | 0.84 | KDM4E (0.60) | ALDH1A1SMN1; SMN2L3MBTL1KMT2ACYP1A2 | |
| SCHEMBL4349193 | 0.84 | KMT2A (0.41) | ALDH1A1KMT2ACYP1A2MAPTMEN1 | |
| SCHEMBL23619188 | 0.83 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL846855 | 0.81 | SCN10A (0.58) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL18922591 | 0.80 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL7028984 | 0.80 | KDM4E (0.50) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 | |
| SCHEMBL14491782 | 0.80 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1SCN10AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321049-A1 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | Petragen, Inc. | 2023-10-12 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-10766912-B2 | Silicon-containing compound for resistance to hepatitis C virus infection | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-08 | — | — | US | disclosed |
| US-20200231547-A1 | 2-(1,1'-BIPHENYL)-1H-BENZODIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2020-07-23 | — | — | US | disclosed |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20100298360-A1 | SMALL MOLECULE INHIBITORS OF PDZ INTERACTIONS | BELMARES MICHAEL P | 2010-11-25 | — | — | US | disclosed |
| US-20100298360-A1 | SMALL MOLECULE INHIBITORS OF PDZ INTERACTIONS | BELMARES MICHAEL P | 2010-11-25 | — | — | US | disclosed |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100160240-A1 | TREATMENT FOR EPILEPSY | ARBOR VITA CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | ARBOR VITA CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | ARBOR VITA CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090036376-A1 | Treatment for Anxiety | NONO INC. (CA) | 2009-02-05 | — | — | US | disclosed |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | NONO INC. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-7217720-B2 | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | ALDH1A1 4365/4885SMN1; SMN2 3220/4885L3MBTL1 1478/4885 |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | ALDH1A1 2404/4885SMN1; SMN2 1240/4885L3MBTL1 151/4885 |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | ALDH1A1 1890/4885SMN1; SMN2 1715/4885L3MBTL1 1306/4885 |
| US-20200231547-A1 | 2-(1,1'-BIPHENYL)-1H-BENZODIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES | APLNR, AP3B1, AP2B1 | ALDH1A1 546/4885SMN1; SMN2 4226/4885L3MBTL1 3605/4885 |
| US-20230321049-A1 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | ALDH1A1 4610/4885SMN1; SMN2 593/4885L3MBTL1 2281/4885 |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | AURKA, AURKB, AURKC | ALDH1A1 3035/4885SMN1; SMN2 3504/4885L3MBTL1 801/4885 |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | ALDH1A1 4365/4885SMN1; SMN2 3220/4885L3MBTL1 1478/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | ALDH1A1 592/4885SMN1; SMN2 434/4885L3MBTL1 699/4885 |
| US-20100298360-A1 | SMALL MOLECULE INHIBITORS OF PDZ INTERACTIONS | PDLIM5, DAB2IP, PSD | ALDH1A1 4365/4885SMN1; SMN2 3220/4885L3MBTL1 1478/4885 |
| US-10766912-B2 | Silicon-containing compound for resistance to hepatitis C virus infection | SLC11A2, SLC10A1, SLC39A11 | ALDH1A1 3793/4885SMN1; SMN2 1177/4885L3MBTL1 3568/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | ALDH1A1 1890/4885SMN1; SMN2 1715/4885L3MBTL1 1306/4885 |
| US-20090036376-A1 | Treatment for Anxiety | GRIN2A, GRIN3A, GRIN1 | ALDH1A1 996/4885SMN1; SMN2 3472/4885L3MBTL1 2851/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | ALDH1A1 2705/4885SMN1; SMN2 1466/4885L3MBTL1 1042/4885 |
| US-20100160240-A1 | TREATMENT FOR EPILEPSY | GRIK5, GRIN3A, GRIN2A | ALDH1A1 3020/4885SMN1; SMN2 1853/4885L3MBTL1 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.